Cancer drug trials often do not report on cardiovascular outcomes; CVS is investing in affordable housing to reduce overall healthcare costs; a drug for obsessive compulsive disorder that was developed through artificial intelligence will soon be tested in humans.
An upcoming issue of the Journal of the American College of Cardiology contains study results showing how almost 40% of cancer clinical trials do not contain data on cardiovascular disease (CVD) events, according to MedPage Today. The study authors expressed concern, because a main goal of cancer treatment is to limit CVD as an adverse effect, also finding discrepancies in how CVD is defined among trials and calling for “more objective thresholds of CVD identification.” They suggest more optimized cancer trials that make a point to include patients with CVD risk factors.CVS Health will invest $75 million in affordable housing in 2020, reports Forbes, which is close to 12% more than its $67-million investment in 2019. The move is meant to address upfront social determinants of health, such as food insecurity and homelessness, that drive up patient costs. UnitedHealth Group and Anthem are doing the same. Down the line, insurers could see reduced costs through avoided hospital stays and averted health crises. Since 1997, CVS and Aetna—its health insurance unit and partner since 2018—have invested over $1 billion in this space, for more than 93,000 affordable rental units.
Individuals with obsessive-compulsive disorder (OCD) have a potential new treatment, with the recent start of a phase 1 clinical trial of an artificial intelligence (AI)-developed medicine, says European Pharmaceutical Review. Sumitomo Dainippon Pharma in Japan and Exscienta in the United Kingdom jointly developed the long-acting, potent serotonin 5-HT1A receptor agonist in less than 12 months via AI—compared with the typical 5 years through conventional means. AI has been used before, to positive results, with a recent study in Nature showing its success in diagnosing breast cancer compared with physicians.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Real-World Data Show Leqvio's Effectiveness in Reducing LDL-C in Patients With ASCVD
April 11th 2024Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% reduction in the usual care group.
Read More